Trevi Therapeutics, Inc. (TRVI) Earnings Call Transcript & Summary

November 10, 2022

NASDAQ US Health Care Pharmaceuticals earnings 18 min

Earnings Call Speaker Segments

Jennifer Good

executive
#1

Good afternoon, and thanks for being with us on our third quarter earnings call and business update. On the line with me today is Lisa Delfini, who serves as Trevi's Chief Financial Officer. Lisa and I will give a few brief prepared remarks, and after that we'll take questions at the conclusion of the call. When it comes to executing on our business plan, this year has been an exciting one for Trevi, and the third quarter followed suit. As we had anticipated, in September the complete trial results came out for our CANAL trial in chronic cough and Idiopathic Pulmonary Fibrosis, or IPF, and they verified the favorable interim findings that had been reported earlier, demonstrating a meaningful decrease in cough frequency relative to baseline, and they were highly statistically significant across both the primary endpoint and several key secondary endpoints; this encompassed objective cough measures, patient-reported outcomes regarding cough frequency and severity, as well as investigator-reported improvements in cough. In the middle of September, we held an R&D day so we could go over these results in depth, together with the PN results, and we heard from prominent KOLs in cough and itch. Rather than going through all of that information again, I'd like to give you an update on what we've been doing since our R&D day. Our lead indication has become chronic cough in IPF, and we're actively working on protocols for the next phase of development while engaging with the FDA and getting ready for interactions with European regulatory authorities. Haduvio is the lead therapy being developed for cough and IPF and is the sole one that has demonstrated positive results in a blinded study for this indication. IPF is a severe end-of-life disease, and chronic cough represents a major source of morbidity, heavily affecting the patient's quality of life. While there is a great deal we can learn from the development currently underway in the refractory chronic cough space, there are distinct elements within the IPF patient population tied not only to the possible effect on the underlying disease, but also to safety given how frail this patient population is. As we get ready for this next step in development, we want to ensure we're aligned with the regulators. At the same time, the clinical teams are getting the study ready so that we can begin once we have agency agreement on the protocol and an open IND; we anticipate starting the next study in the first half of 2023, and we'll give guidance on the overall design as well as the timing for the trial and results when we begin the study. Dr. Toby Maher has presented our data in cough and IPF as a late breaker at the European Respiratory Society, and it was also presented at ICLAF. This month, Dr. Philip Molyneaux will present the full data at the British Thoracic Society meeting. We're also in the process right now of preparing a manuscript to publish the trial results. The IPF cough data has drawn attention and support from KOLs and pulmonologists around the world. Another area where our efforts continue is prurigo nodularis, or PN — a severe, debilitating condition marked by skin papules and nodules, along with relentless, intense itching. Positive results from the phase II-B/III PRISM study in PN were also shared by us in June. Statistical significance was reached by the trial on the primary endpoint and every key secondary endpoint. A number of patients remain enrolled in the one-year open-label extension study, and the final patient is expected to finish in February 2023. At the same time, we are finishing up all the different clinical reports and documents while getting ready to ask for an end-of-phase II meeting with the FDA, which should take place during the first half of 2023. Dr. Sonja Ständer delivered an oral presentation of our PN data at the European Academy of Dermatology and Venereology in September, and right now we are drafting a manuscript to publish the complete study results, plus abstracts for a number of additional dermatology meetings. Things are busy at Trevi as we get ready for forthcoming regulatory meetings spanning indications, build out the protocols for the next stage of development, and locate sites for our upcoming study. Progress has been solid, and we look forward to sharing further details with you as we prepare to launch the next studies. Looking back at 2022, the execution shown by our team and the encouraging trial results across both of our lead indications make me incredibly proud. The trial data and the financings that followed have put us in a strong position to keep developing Haduvio not just in IPF chronic cough, but in other serious chronic cough conditions too. Regarding PN, talks are underway with possible partners to move that program forward into the next stage of clinical development. I'll now hand things over to Lisa for a review of our financial results, after which we will open the line for questions.

Lisa Delfini

executive
#2

Thanks, Jennifer, and good afternoon to all of you. Just a quick note that you can find the complete financial results for the three and nine months that ended September 30th, 2022 in the press release we issued before this call, as well as in our 10-Q, which we filed with the SEC today after the market closed. For the third quarter of 2022, our net loss came in at $8.3 million, versus a net loss of $7.3 million in the same quarter of 2021. R&D expenses totaled $5.8 million in the third quarter of 2022, compared with $4.7 million during the same period of 2021. The main driver here was start-up activities for our planned trials, which included buying clinical trial supplies and higher expense tied to the timing of activity in our phase II CANAL trial relative to the third quarter of 2021. Those increases were partly offset by lower expenses for activities in our PRISM trial, thanks to the completion of the blinded portion of that trial in the second quarter of 2022. G&A expenses came to $2.6 million in the third quarter of 2022, versus $2.2 million in the same period of 2021. That increase was mainly attributable to higher legal fees tied to intellectual property and greater market research costs. During the quarter, following the announcement of positive results for the full data in our CANAL trial, we brought in gross proceeds of approximately $55 million from both new and existing investors through a public offering; we also received $5.9 million in proceeds during the quarter from the exercise of previously issued warrants. After the quarter ended, we received an additional $3.1 million in proceeds from the underwriter's option for the greenshoe tied to the September offering; we finished October with a cash and investments balance of roughly $125.7 million, which we've invested in a portfolio of high credit quality marketable securities and which is generating healthy interest income for us in today's higher interest rate environment. That provides us with cash runway into 2026 to carry out the plans Jennifer laid out today and to pay off our term loan in accordance with its terms between now and February 1st, 2024. To wrap up, I'm glad to welcome our new investors to Trevi, and I'm grateful for our existing investors, including those who took part in this latest funding round. I look forward to supporting our Trevi team with financial discipline as we negotiate agreements and execute the next phase of development for Haduvio. That wraps up our prepared remarks. I'll now hand the call back to the operator for Q&A.

Annabel Samimy

analyst
#3

Hello, everyone, and thank you for allowing me to ask. There are a couple of things I wanted to bring up. One of them, I believe, concerns what requests you'll be making to the regulatory bodies concerning how the upcoming IPF study gets designed. Do you have plans to examine any fresh endpoints, or to include combination use alongside the standard therapy for these patients? In addition, what do you think about how recruitment might go, now that COVID appears to have settled, and do you expect that enrollment in these studies could become somewhat easier, considering how much time the initial phase II-A required? Perhaps those are the first points I could raise. Thank you.

Jennifer Good

executive
#4

Yes. Thanks, Annabel. Talks are ongoing with the agency. I'd put it this way: we aren't attempting to build some brand-new approach to endpoints. This objective cough monitor has had the FDA's backing, and that is the very tool we employed in our phase II study. My expectation is that we'll go that route. Validation in the IPF population will be necessary for us. On top of that, we'll have to identify a patient-reported outcome that shifts in that same direction. Since every one of our secondaries also came out statistically significant, my sense is that we simply need to select one and then put in the effort. That doesn't concern me much. In this particular trial, we allowed patients to receive the drug alongside standard of care. As you may recall, roughly half our patients were taking antifibrotics. The only requirement was that they'd been stable for a minimum of eight weeks. Once again, staying somewhat with our prior approach, I'd say we're currently grinding through inclusion and exclusion criteria, and making sure the overall study design holds up. What I mean is, the point of the upcoming phase II trial will really center on identifying the minimally effective dose. Based on what our data showed, we saw an effect quite early. We'll have to sort through that and truly address the dosing question. It's just about making certain the protocol is locked down. Regarding your question on enrollment, that's a fair one, and I wish COVID were the sole obstacle; with these patients, it's anything—you know, RSV, colds, all of it. That said, I'd point out the distinction here: we conducted that study only within the U.K., which restricts you to something like 10 or 12 sites. This time we'll expand into the U.S. and in all likelihood Germany too. That gives us far more sites, which should let us push through enrollment. With any luck, that provides a bit more of a buffer.

Annabel Samimy

analyst
#5

Okay. Could I just pose a few more questions? At present you're sitting at close to $126 million. Are you considering looking into other chronic cough indications at this point, or will that simply remain on the back burner? Moving on to PN, it sounds like you're clearly still looking for a partner, but should nobody show interest, are you prepared to proceed on your own? Do you possess the money needed to pursue every one of those opportunities? Thanks.

Jennifer Good

executive
#6

Right. Regarding the additional chronic cough indications, a phase II refractory chronic cough trial is something we have interest in conducting. We've kind of indicated, I believe, that we'll aim to get that started, ideally around the middle of the year. I really want to get the IPF cough program moving and underway. That, you know, will be our main area of emphasis here, along with finishing up PN and making it through the agency meeting. My expectation is that by the middle of the year, we'll hopefully be launching a refractory chronic cough study. Enrollment should go fairly fast. Those kinds of trials bring patients in at a much quicker pace, so we'd hope to complete it in roughly 6 to 9 months. When it comes to PN, that has not been included in this $126 million. I believe we're in ongoing talks with a number of partners. Right now, we don't intend to conduct the final study on our own. Hopefully we'll manage to secure a partner for that, I think, since we truly want to direct this money toward the cough portfolio as a priority.

Annabel Samimy

analyst
#7

Okay, great. Thank you.

Jennifer Good

executive
#8

Yeah.

Serge Belanger

analyst
#9

Hello there, good afternoon. I have a few things to ask. I suppose starting with the cough program — any reactions now that the complete data set came out roughly 2 months back? It seems. You said this data set is going to be shown at the thoracic meeting later this month. I'm just wondering whether further analyses of the data will be included in that presentation. That's my first one.

Jennifer Good

executive
#10

Yes. Thanks, Serge. Regarding reactions to the complete data set, well, you've looked at it. It matched the interim remarkably well, which was encouraging for us. I'd say it was equally robust; we could connect it to our 24-hour cough data, and we plan to proceed with that as an endpoint since it appeared in the full analysis set. The response, I think, has simply been very positive. I've attended many of these medical meetings, and it certainly drew interest from pulmonologists as well as the entire cough community. The reaction, I'd say, has been positive. Your next question was-

Lisa Delfini

executive
#11

Thoracic meeting.

Jennifer Good

executive
#12

Right, the British Thoracic Society. As you know, we've already presented a great deal. Unfortunately, that falls during Thanksgiving weekend, which means we won't attend. My guess is the Brits schedule it that way deliberately. We revealed a huge amount of data during our R&D day, I'd say. There may be a few additional items in there, and Serge, if that interests you, I'm happy to forward the presentation. I believe our sharing of what exists has been quite thorough. The place where I think you'll get a comprehensive look is once the manuscript is published, since a tremendous amount of effort is underway with all the key opinion leaders in this field on putting the data into that manuscript.

Serge Belanger

analyst
#13

All right. Regarding PN, perhaps just — you know, I realize it hasn't been long since you chose to seek a partner for that, so maybe you could share a bit about the discussions you've been having and whether the recent Dupixent approval might spark more interest in that indication.

Jennifer Good

executive
#14

Yes. This need is definitely something people grasp. PN, I mean, it's on folks' radar screens. They're interested. An oral having a significant role in the treatment sequence of therapy is something everyone accepts. My sense is Dupixent will help boost patient numbers. Just last week I was presenting at a conference, and there was considerable discussion about how, you know, big pharma excels at identifying these diseases and boosting patient numbers. All of that, I think, is genuinely helpful. What I'd like is to get through our FDA meeting and receive clear FDA guidance, so that as we move forward, a payer or a partner will have a very clear picture of the path forward. Yes, I believe it does help. Having a biologic here actually benefits the overall market — that's always been part of our thesis.

Serge Belanger

analyst
#15

Alright, I appreciate the briefing.

Jennifer Good

executive
#16

Yes, thanks, Serge.

Jennifer Good

executive
#17

We appreciate everyone joining us on this call today, and we look forward to seeing some of you at the Stifel Investor Conference taking place next week as well as in San Francisco during January. Thanks.

Operator

operator
#18

That wraps up our call. We appreciate everyone joining us for today's presentation, and at this point you're free to leave the line.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Trevi Therapeutics, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Trevi Therapeutics, Inc. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Trevi Therapeutics, Inc. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.